GlassScriptPhysician profile
Matthew J Skoner
NPI 1952894495
$1,104.63
in general payments reported to CMS, 2019-2025
15 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.82 · 2021: $176 · 2022: $157 · 2023: $132 · 2024: $224 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $280.95 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Sun Pharmaceutical Industries INC. | $172.12 | 2021-2025 | Cequa |
| Alcon Vision LLC | $154.92 | 2023-2025 | Rocklatan, Tryptyr |
| Amgen INC. | $84.18 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $78.01 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $76.18 | 2020-2022 | |
| Allergan, INC. | $38.62 | 2021 | |
| Coopervision INC. | $37.95 | 2021 | |
| Bausch & Lomb Americas INC. | $35.87 | 2025 | Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $33.06 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.98 | 2021 | |
| Dompe US, INC. | $26.57 | 2025 | Oxervate |
| Sight Sciences, INC. | $20.17 | 2024 | Omni Surgical System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Thea Pharma INC. | $16.65 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Skoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.